Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity.

@article{Marsh1987SurvivalAA,
  title={Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity.},
  author={Judith C. W. Marsh and Jill M Hows and K A Bryett and S Al-Hashimi and S M Fairhead and Edward C Gordon-Smith},
  journal={Blood},
  year={1987},
  volume={70 4},
  pages={1046-52}
}
Sixty-four patients with aplastic anemia were treated with antilymphocyte globulin (ALG Merieux) between 1980 and 1985. The actuarial survival for all patients was 53% at 6 years, with 79% survival for nonsevere aplastic anemia (NSAA) and 36% for severe aplastic anemia (SAA). The neutrophil and platelet counts before treatment with ALG were highly predictive of survival, whereas sex, age, and etiology were not. Duration of disease prior to ALG treatment was inversely related to survival… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Management of the refractory aplastic anemia patient: what are the options?

Hematology. American Society of Hematology. Education Program • 2013
View 3 Excerpts

Clinical course of non-severe aplastic anemia in adults.

International journal of hematology • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…